Premium
The human metapneumovirus: a case series and review of the literature
Author(s) -
Shahda S.,
Carlos W.G.,
Kiel P.J.,
Khan B.A.,
Hage C.A.
Publication year - 2011
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/j.1399-3062.2010.00575.x
Subject(s) - human metapneumovirus , medicine , ribavirin , metapneumovirus , pneumonia , viral pneumonia , intensive care medicine , immunology , pediatrics , disease , virology , respiratory system , virus , respiratory tract infections , covid-19 , infectious disease (medical specialty) , hepatitis c virus
S. Shahda, W.G. Carlos, P.J. Kiel, B.A. Khan, C.A. Hage. The human metapneumovirus: a case series and review of the literature
Transpl Infect Dis 2011: 13: 324–328. All rights reserved Abstract: Human metapneumovirus (hMPV) is an emerging human pulmonary pathogen that is genetically related to respiratory syncytial virus. It has been increasingly associated with respiratory illnesses over the last few decades. Immunocompromised patients are particularly susceptible with resultant morbidity and mortality. We describe our experience with 9 immunocompromised patients diagnosed with pneumonia secondary to hMPV, 2 of whom were successfully treated with aerosolized and oral ribavirin along with intravenous immunoglobulin (IVIG). We suggest that hMPV should be considered in the differential diagnosis of immunocompromised patients with acute respiratory illness. Ribavirin (oral and aerosolized) with IVIG is potentially an effective treatment option for those with severe disease.